162 related articles for article (PubMed ID: 22369131)
1. Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors.
Tamiya H; Kamo R; Kumei A; Yanagihara S; Ishii M; Kobayashi H
Clin Exp Dermatol; 2012 Oct; 37(7):749-52. PubMed ID: 22369131
[TBL] [Abstract][Full Text] [Related]
2. Angiosarcoma of the scalp successfully treated with a single therapy of sorafenib.
Ono S; Tanioka M; Fujisawa A; Tanizaki H; Miyachi Y; Matsumura Y
Arch Dermatol; 2012 Jun; 148(6):683-5. PubMed ID: 22710450
[No Abstract] [Full Text] [Related]
3. Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
Smolle E; Taucher V; Petru E; Haybaeck J
Anticancer Res; 2014 Apr; 34(4):1519-30. PubMed ID: 24692678
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib can preserve cosmetic quality of life even in end-stage angiosarcoma.
Kitamura S; Hata H; Imafuku K; Haga N; Homma E; Shimizu H
Clin Exp Dermatol; 2015 Dec; 40(8):931-3. PubMed ID: 25817046
[No Abstract] [Full Text] [Related]
5. Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma.
Erös de Bethlenfalva-Hora C; Mertens JC; Piguet AC; Kettenbach J; Schmitt J; Terracciano L; Weimann R; Dufour JF; Geier A
Clin Sci (Lond); 2014 Feb; 126(3):243-52. PubMed ID: 23822114
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib in patients with refractory or recurrent multiple myeloma.
Yordanova A; Hose D; Neben K; Witzens-Harig M; Gütgemann I; Raab MS; Moehler T; Goldschmidt H; Schmidt-Wolf IG
Hematol Oncol; 2013 Dec; 31(4):197-200. PubMed ID: 23494836
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib in squamous cell carcinoma of the head and neck: molecular basis and potential role.
Bhatt VR; Ganti AK
Future Oncol; 2014 Jan; 10(1):17-20. PubMed ID: 24328406
[No Abstract] [Full Text] [Related]
8. Sorafenib: targeting multiple tyrosine kinases in cancer.
Hasskarl J
Recent Results Cancer Res; 2014; 201():145-64. PubMed ID: 24756790
[TBL] [Abstract][Full Text] [Related]
9. Angiosarcoma of the scalp and face: failure of an interferon alpha treatment.
Guillot B; Raison-Peyron N; Acevedo M; Meunier L; Dandurand M; Meynadier J
Eur J Dermatol; 2000 Jun; 10(4):300-2. PubMed ID: 10846259
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib in renal cell carcinoma.
Davoudi ET; bin-Noordin MI; Javar HA; Kadivar A; Sabeti B
Pak J Pharm Sci; 2014 Jan; 27(1):203-8. PubMed ID: 24374450
[TBL] [Abstract][Full Text] [Related]
11. Complete long-term response of angiosarcoma of the scalp with cervical lymph node metastases treated with a combination of weekly and monthly docetaxel.
Nakamura Y; Nakamura Y; Hori E; Furuta J; Kawachi Y; Otsuka F
Br J Dermatol; 2010 Dec; 163(6):1357-8. PubMed ID: 20731655
[No Abstract] [Full Text] [Related]
12. Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face.
Tokuyama W; Mikami T; Masuzawa M; Okayasu I
Hum Pathol; 2010 Mar; 41(3):407-14. PubMed ID: 19913279
[TBL] [Abstract][Full Text] [Related]
13. Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
Hittinger M; Staehler M; Schramm N; Ubleis C; Becker C; Reiser M; Berger F
Urol Oncol; 2012 Sep; 30(5):695-703. PubMed ID: 21865061
[TBL] [Abstract][Full Text] [Related]
14. Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report.
Yang L; Liu L; Han B; Han W; Zhao M
BMC Cancer; 2018 May; 18(1):618. PubMed ID: 29855279
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).
Chevreau C; Le Cesne A; Ray-Coquard I; Italiano A; Cioffi A; Isambert N; Robin YM; Fournier C; Clisant S; Chaigneau L; Bay JO; Bompas E; Gauthier E; Blay JY; Penel N
Cancer; 2013 Jul; 119(14):2639-44. PubMed ID: 23589078
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
Grenader T; Rosenbaum E; Zilber S; Bogot N; Shavit L
Clin Genitourin Cancer; 2013 Jun; 11(2):201-3. PubMed ID: 23266054
[No Abstract] [Full Text] [Related]
17. Early detection of cutaneous angiosarcoma of the face and scalp and treatment with placitaxel.
Pestoni C; Paredes-Suarez C; Peteiro C; Toribio J
J Eur Acad Dermatol Venereol; 2005 May; 19(3):357-9. PubMed ID: 15857466
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib for ovarian cancer.
Leone Roberti Maggiore U; Valenzano Menada M; Venturini PL; Ferrero S
Expert Opin Investig Drugs; 2013 Aug; 22(8):1049-62. PubMed ID: 23675696
[TBL] [Abstract][Full Text] [Related]
19. Angiosarcoma of the scalp successfully treated with pazopanib.
Tomita H; Koike Y; Asai M; Ogawa F; Abe K; Tanioka M; Utani A
J Am Acad Dermatol; 2014 Jan; 70(1):e19-21. PubMed ID: 24176520
[No Abstract] [Full Text] [Related]
20. Complete remission in a patient with multifocal metastatic cutaneous angiosarcoma with a combination of paclitaxel and sorafenib.
Donghi D; Dummer R; Cozzio A
Br J Dermatol; 2010 Mar; 162(3):697-9. PubMed ID: 20030640
[No Abstract] [Full Text] [Related]
[Next] [New Search]
